Patents Assigned to Tularik
-
Publication number: 20040248882Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.Type: ApplicationFiled: March 25, 2004Publication date: December 9, 2004Applicant: Tularik Inc.Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
-
Publication number: 20040235911Abstract: Hydroxyamidines and related compounds are provided which are suitable as antibacterial agents.Type: ApplicationFiled: June 25, 2004Publication date: November 25, 2004Applicant: Tularik Inc.Inventors: Leping Li, Xiaoqi Chen, Pingchen Fan, Jeffrey Thomas Mihalic, Serena Cutler
-
Patent number: 6821750Abstract: The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, ABCG8. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of ABCG8.Type: GrantFiled: November 20, 2001Date of Patent: November 23, 2004Assignees: Tularik Inc., Board of Regents, The University of Texas SystemInventors: Helen H. Hobbs, Bei Shan, Robert Barnes, Hui Tian
-
Patent number: 6822001Abstract: Combination therapies are provided for the treatment of proliferative disorders which use a pentafluorobenzenesulfonamide of formula I and an antineoplastic agent such as gemcitabine or paclitaxel.Type: GrantFiled: November 2, 2001Date of Patent: November 23, 2004Assignee: Tularik Inc.Inventors: Susan Schwendner, Pieter Timmermans, Jacqueline Walling
-
Patent number: 6818419Abstract: The present invention provides nucleic acids and polypeptides for IRAK-4, a novel member of the IRAK family of protein kinases. Members of the IRAK family are indispensable signal transducer for members of the IL-1R/Toll family of transmembrane receptors, including IL-1 receptors, IL-18 receptors and LPS receptors. IRAK-4 sequences from human and mouse are provided, as are methods for identifying compounds useful in the treatment or prevention of inflammatory diseases.Type: GrantFiled: January 11, 2001Date of Patent: November 16, 2004Assignee: Tularik Inc.Inventors: Holger Wesche, Shyun Li
-
Patent number: 6809104Abstract: Compounds having the formula: wherein L is a bond or (C1-C4)alkylene, R″ is hydrogen or (C1-C8)alkyl, and R1, R2, R4, R, R′, and the subscript n are as described herein, are provided, which are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. Pharmaceutical compositions and methods of using these compounds for the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor, such as eating disorders, obesity, anxiety disorders and mood disorders, are also provided.Type: GrantFiled: November 6, 2002Date of Patent: October 26, 2004Assignee: Tularik Inc.Inventors: Xiaoqi Chen, Pingchen Fan, Juan Jaen, Leping Li, Mike Lizarzaburu, Jeffrey Thomas Mihalic, Stephen Joseph Shuttleworth
-
Publication number: 20040209871Abstract: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.Type: ApplicationFiled: November 21, 2003Publication date: October 21, 2004Applicants: Tularik Inc., Japan Tobacco Inc.Inventors: Brian M. Fox, Noboru Furukawa, Xiaolin Hao, Kiyosei Iio, Takashi Inaba, Simon M. Jackson, Frank Kayser, Marc Labelle, Kexue Li, Takuya Matsui, Dustin L. McMinn, Nobuya Ogawa, Steven M. Rubenstein, Shoichi Sagawa, Kazuyuki Sugimoto, Masahiro Suzuki, Masahiro Tanaka, Guosen Ye, Atsuhito Yoshida, Jian Zhang
-
Patent number: 6794379Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.Type: GrantFiled: June 6, 2002Date of Patent: September 21, 2004Assignee: Tularik Inc.Inventors: Julio C. Medina, Michael G. Johnson, An-Rong Li
-
Publication number: 20040176426Abstract: The present invention provides compounds, pharmaceutical compositions and methods that are useful in modulating the farnesoid X receptor (FXR). As FXR is involved in negatively controlling the expression level of cholesterol 7&agr;-hydroxylase (cyp7a), the rate-limiting enzyme involved in the oxidative metabolism of cholesterol into bile acids, the compounds described herein find utility in treating diseases associated with abnormally high or low cholesterol levels. In certain aspects, the FXR modulators (e.g., antagonists) described herein block the negative feed-back downregulation of cyp7a expression produced by certain cholic acids, the endogenous ligands for FXR. Moreover, as FXR forms heterodimers with the retinoid X receptor (RXR) in some cell types, modulation of the level of FXR activity in cells has a wide range of effects on a variety of biological processes which are mediated by RXR or other RXR-interacting proteins such as PPAR&ggr; and PPAR&agr;.Type: ApplicationFiled: March 4, 2004Publication date: September 9, 2004Applicant: Tularik, Inc.Inventors: Jonathan Houze, Sharon McKendry, Joshua P. Gergely, Yi Xia, Bei Shan, Frank Kayser
-
Publication number: 20040176409Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR&ggr;. In particular, the compounds of the invention modulate the function of PPAR&ggr;. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.Type: ApplicationFiled: November 20, 2003Publication date: September 9, 2004Applicants: Tularik Inc, Japan Tobacco, Inc.Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
-
Patent number: 6780858Abstract: Hydroxyamidines and related compounds are provided which are suitable as antibacterial agents.Type: GrantFiled: January 12, 2001Date of Patent: August 24, 2004Assignee: Tularik Inc.Inventors: Leping Li, Xiaoqi Chen, Pingchen Fan, Jeffrey Thomas Mihalic, Serena Cutler
-
Patent number: 6777446Abstract: The present invention provides compounds, pharmaceutical compositions and methods that are useful in modulating the farnesoid X receptor (FXR). As FXR is involved in negatively controlling the expression level of cholesterol 7&agr;-hydroxylase (cyp7a), the rate-limiting enzyme involved in the oxidative metabolism of cholesterol into bile acids, the compounds described herein find utility in treating diseases associated with abnormally high or low cholesterol levels. In certain aspects, the FXR modulators (e.g., antagonists) described herein block the negative feed-back downregulation of cyp7a expression produced by certain cholic acids, the endogenous ligands for FXR. Moreover, as FXR forms heterodimers with the retinoid X receptor (RXR) in some cell types, modulation of the level of FXR activity in cells has a wide range of effects on a variety of biological processes which are mediated by RXR or other RXR-interacting proteins such as PPAR&ggr; and PPAR&agr;.Type: GrantFiled: August 31, 2001Date of Patent: August 17, 2004Assignee: Tularik, Inc.Inventors: Jonathan Houze, Sharon McKendry, Joshua P. Gergely, Yi Xia, Bei Shan, Frank Kayser
-
Publication number: 20040152132Abstract: The invention provides solid support synthetic methods for producing combinatorial libraries of modulators of LXRs. The combinatorial libraries thus produced are useful both as diagnostic indicators of LXR&agr; function and as pharmacologically active agents. The combinatorial libraries find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.Type: ApplicationFiled: December 30, 2003Publication date: August 5, 2004Applicants: Tularik Inc., Sumitomo Pharmaceuticals Co., Ltd.Inventors: Julio Medina, Naonori Imazaki
-
Patent number: 6770648Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.Type: GrantFiled: July 30, 2002Date of Patent: August 3, 2004Assignee: Tularik Inc.Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
-
Patent number: 6740682Abstract: The novel compound 3-amidinobenzoyl-D-phenylglycine-3-phenylanilide is useful as a serine protease inhibitor.Type: GrantFiled: November 19, 2001Date of Patent: May 25, 2004Assignee: Tularik LimitedInventor: John Walter Liebeschuetz
-
Publication number: 20040097485Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.Type: ApplicationFiled: September 19, 2003Publication date: May 20, 2004Applicant: Tularik Inc.Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, Xian Yun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Andrew Smith, Marie-Louise Smith
-
Patent number: 6727267Abstract: Compounds, compositions and methods are provided that are useful in the treatment and prevention of certain viral infections and associated diseases. In particular, the compounds of the invention inhibit the activity of a viral RNA polymerase. The subject methods are particularly useful in the treatment of diseases causes by hepatitis C virus infection.Type: GrantFiled: April 5, 2001Date of Patent: April 27, 2004Assignee: Tularik Inc.Inventors: Juan C. Jaen, Jay P. Powers
-
Publication number: 20040039035Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.Type: ApplicationFiled: September 2, 2003Publication date: February 26, 2004Applicants: Tularik Inc., ChemoCentryx, Inc.Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
-
Publication number: 20040029232Abstract: The invention provides isolated nucleic acid and amino acid sequences of four novel G-protein coupled receptors that are amplified in breast cancer cells, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of G-protein coupled receptors.Type: ApplicationFiled: August 4, 2003Publication date: February 12, 2004Applicant: Tularik Inc.Inventors: Scott Powers, Jianxin Yang, Gene Cutler
-
Patent number: 6682898Abstract: This invention provides receptor peptides that have a high affinity for STAT4 and STAT6 polypeptides. Also provided are assays that are useful for identifying compounds that modulate the interaction between STAT4 and STAT6 polypeptides and their respective cellular promoters. The assays are amenable to high throughput screening.Type: GrantFiled: March 26, 2001Date of Patent: January 27, 2004Assignee: Tularik Inc.Inventors: Pengguang Wu, Judi McKinney